AAP
AVBP icon

Arax Advisory Partners’s ArriVent BioPharma AVBP Stock Holding History

Arax Advisory Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.61K Buy
330
+139
+73% +$3.14K ﹤0.01% 2587
2025
Q4 		$3.84K Sell
191
-97
-34% -$2.02K ﹤0.01% 2991
2025
Q3 		$5.31K Buy
+288
New +$5.66K ﹤0.01% 2852
2025
Q1 		– Sell
-119
Closed -$3.17K – 3090
2024
Q4 		$3.17K Hold
119
– – ﹤0.01% 1894
2024
Q3 		$2.8K Hold
119
– – ﹤0.01% 1933
2024
Q2 		$2.21K Buy
+119
New +$2.12K ﹤0.01% 1934

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Arax Advisory Partners's AVBP Position: Q1 2026 in Review

Arax Advisory Partners increased its ArriVent BioPharma (AVBP) stake by 73% in Q1 2026, buying an estimated $3.14K and bringing the position to 330 shares worth $7.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2587.

Arax Advisory Partners first reported a position in AVBP in Q2 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Arax Advisory Partners held 330 shares of ArriVent BioPharma worth $7.61K as of Q1 2026.
  • Arax Advisory Partners bought 139 ArriVent BioPharma shares in Q1 2026, an estimated $3.14K.
  • ArriVent BioPharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2587 holding.
  • Arax Advisory Partners first reported a position in ArriVent BioPharma in Q2 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.